The Liver Engineering Committee focuses on how to create or obtain a new liver.
Transplantation of a donor liver from human to human is the current standard in treating liver failure. However, this process is not close to providing the number of replacement livers for patients in need. Transplanting a human liver grown in an animal may be possible though it is undesirable due to regulatory and safety issues. Therefore, other bioengineering techniques are sought such as decellularized animal livers that are recellularized to match donor cells and organ size. Bioprinting is also a strong opportunity for producing new liver tissues or whole organize.
One main focus of this committee is in defining how to measure success in producing new engineered liver tissue. There may be multiple end-products that can be usable in the clinic. For example, creating liver tissue as a bridge to further transplant may be a first viable product for liver engineering. Furthering this to maintaining life with normal liver function could be a second step beyond this. This committee will also focus on defining identifiable biomarkers to help track success metrics in engineered tissues.
Please log in again. The login page will open in a new tab. After logging in you can close it and return to this page.